Illumina stock trades on Nasdaq as its sequencing business stays central

Illumina Inc. (ISIN US4523271090) trades on Nasdaq and remains a leading name in genetic analysis, with its business built around sequencing systems, consumables and services. The company’s core revenue model is still anchored in the installed base of instruments that drive recurring reagent demand.

Business model

Illumina's portfolio centers on sequencing platforms, which are used in research, clinical and applied settings. That structure gives the company a mix of upfront instrument sales and repeatable consumables revenue, a model that typically makes utilization rates and workflow adoption especially important for investors.

For a US market anchor, Illumina is a Nasdaq-listed life sciences company whose fortunes are closely tied to the pace of demand in genomics and molecular diagnostics. That keeps the stock’s narrative linked more to platform usage and product cadence than to a single headline product cycle.

Product focus

A representative product line is the company's sequencing systems, which are designed to process DNA and RNA samples for research and clinical workflows. In practical terms, that means the product story is not just about one machine, but about the consumables and service relationships that can follow it over time.

That recurring-revenue structure is the key interpretive point for investors: the economics of the franchise depend on how consistently customers keep running the installed base, not only on the next hardware sale.

Market context

Illumina stock is best read through the lens of genomics adoption, capital spending in research and the durability of reagent demand. A company with this profile can look very different from a one-shot diagnostics vendor because a larger share of value comes from long-term platform usage.

As of July 14, 2026, 11:02 p.m. ET, shares trade on Nasdaq in USD.